Opaleye Management as of Sept. 30, 2014
Portfolio Holdings for Opaleye Management
Opaleye Management holds 30 positions in its portfolio as reported in the September 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Chimerix (CMRX) | 16.2 | $21M | 755k | 27.62 | |
| Pharmacyclics | 7.8 | $10M | 85k | 117.43 | |
| Retrophin | 7.0 | $9.0M | 1.0M | 9.02 | |
| Ariad Pharmaceuticals | 6.3 | $8.1M | 1.5M | 5.40 | |
| Agios Pharmaceuticals (AGIO) | 5.4 | $7.0M | 114k | 61.35 | |
| Clovis Oncology | 4.8 | $6.2M | 140k | 44.36 | |
| Cempra | 4.3 | $5.5M | 505k | 10.96 | |
| GenMark Diagnostics | 3.9 | $4.9M | 550k | 8.97 | |
| Ultragenyx Pharmaceutical (RARE) | 3.8 | $4.8M | 85k | 56.60 | |
| Insys Therapeutics | 3.7 | $4.8M | 123k | 38.78 | |
| Inspiremd | 3.6 | $4.6M | 2.1M | 2.20 | |
| Codexis (CDXS) | 3.1 | $3.9M | 1.7M | 2.33 | |
| Bind Therapeutics | 3.0 | $3.9M | 450k | 8.59 | |
| Imprimis Pharmaceuticals | 2.9 | $3.7M | 503k | 7.42 | |
| Prothena (PRTA) | 2.7 | $3.5M | 157k | 22.16 | |
| Tetraphase Pharmaceuticals | 2.6 | $3.4M | 170k | 19.95 | |
| Catalyst Pharmaceutical Partners (CPRX) | 2.5 | $3.2M | 975k | 3.32 | |
| Cardiovascular Systems | 2.3 | $3.0M | 125k | 23.63 | |
| Alnylam Pharmaceuticals (ALNY) | 1.8 | $2.3M | 29k | 78.10 | |
| Celgene Corp right 12/31/2011 | 1.7 | $2.2M | 660k | 3.39 | |
| Aegerion Pharmaceuticals | 1.5 | $1.9M | 58k | 33.38 | |
| Accelr8 Technology | 1.5 | $1.9M | 89k | 21.48 | |
| Dicerna Pharmaceuticals | 1.3 | $1.7M | 135k | 12.73 | |
| Geron Corporation (GERN) | 1.3 | $1.6M | 820k | 2.00 | |
| D Fluidigm Corp Del (LAB) | 1.3 | $1.6M | 67k | 24.50 | |
| Evoke Pharma | 1.1 | $1.5M | 267k | 5.50 | |
| Ophthotech | 1.1 | $1.4M | 35k | 38.93 | |
| Celator Pharmaceuticals | 0.8 | $1.0M | 405k | 2.53 | |
| Biolinerx Ltd-spons | 0.6 | $755k | 490k | 1.54 | |
| Kips Bay Med | 0.0 | $8.5k | 50k | 0.17 |
